Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

9:29 AM ET Form 4
Insider Buying Cleveland-Cliffs Inc. CLF

Cleveland-Cliffs Insider Edilson Camara Buys $99.8K of Stock

Edilson Camara bought 7,400 shares of Cleveland-Cliffs Inc. at $13.49 a share, worth $99.8K in total on Oct 22, 2026. Shares held after the trade: 64,717 (+12.9%).

Value
$99.8K
Shares
7,400
Price
$13.49
Holding change
+12.9%
Trade date
Oct 22, 2026
9:26 AM ET 8-K
Financial Results BV Financial, Inc. BVFL

BV Financial Financial Results

BV Financial, Inc. reported Q3 2026 net income of $3.4 million, or $0.42 per diluted share, compared to $3.7 million in the prior year period. The company highlighted a decrease in total assets to $877.9 million as it utilized loan portfolio cash to repay $30.0 million in FHLB borrowings, while also repurchasing 163,540 shares during the quarter.

Term
Q3 2026
9:24 AM ET 8-K
Financial Results Tompkins Financial Corp TMP

Tompkins Financial Financial Results

Tompkins Financial Corporation reported Q3 2026 net income of $28.7 million, or $2.00 per diluted share, representing a 21.2% increase in EPS compared to the same period in 2025. The results were driven by a 21.0% year-over-year increase in net interest income and expansion of the net interest margin to 3.65%. Additionally, the company's Board of Directors declared a quarterly dividend of $0.74 per share, a 13.8% increase over the prior year's fourth quarter dividend.

Term
Q3 2026

“We are pleased to report strong financial results for the third quarter. Our consistent levels of loan and deposit growth along with further expansion in net interest margin continue to provide momentum as we look forward. Given our strength in earnings and capital position we have approved another dividend increase, payable in the fourth quarter of 2026. This dividend represents a 13.8% increase compared to the dividend paid in the fourth quarter of 2025.”

Stephen Romaine, President and CEO
9:19 AM ET 8-K
Reverse Stock Split Nuwellis, Inc. NUWE

Nuwellis Reverse Stock Split

Nuwellis, Inc. has announced a 1-for-9 reverse stock split of its issued and outstanding common stock, effective October 26, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market under the existing symbol 'NUWE' on October 27, 2026. This action consolidates every nine shares into one share to adjust the company's capital structure.

9:15 AM ET 8-K
Clinical Trial Data Eikon Therapeutics, Inc. EIKN

Eikon Therapeutics Clinical Trial Data

Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.

“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”

Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
9:15 AM ET 8-K
Financial Results Gorman Rupp Co GRC

Gorman Rupp Financial Results

The Gorman-Rupp Company reported record third quarter 2026 financial results, with net sales increasing 11.8% to $193.3 million. Net income rose significantly to $22.7 million, or $0.86 per share, driven by volume growth, price increases, and improved operating leverage across all markets.

Term
Q3 2026
9:04 AM ET 8-K
Loan & Debt Walmart Inc. WMT

Walmart $3B Debt Financing with BNP Paribas Securities Corp.

Walmart Inc. entered into pricing agreements to issue $3.0 billion in aggregate principal amount of senior notes across four tranches with maturities ranging from 2029 to 2036. Additionally, the company announced a multi-tranche offering of Canadian-dollar denominated notes totaling C$5.0 billion. The proceeds from these debt issuances are intended for general corporate purposes.

Value
$3B
Counterparty
BNP Paribas Securities Corp., BofA Securities, Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC
Term
through 2036
9:03 AM ET 8-K
M&A Deal Arcosa, Inc. ACA

Arcosa M&A Deal with CRH Americas, Inc.

Arcosa, Inc. completed its merger with CRH Americas, Inc., a subsidiary of CRH plc, resulting in Arcosa becoming a wholly owned subsidiary of CRH. Under the terms of the agreement, Arcosa stockholders received $150.00 in cash for each share of common stock held. In connection with the closing, Arcosa terminated its $1.4 billion senior secured credit facility and repaid approximately $450.1 million in outstanding obligations.

Counterparty
CRH Americas, Inc.
9:01 AM ET 8-K
Licensing Deal Tempus AI, Inc. TEM

Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M

Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.

Value
$192M
Counterparty
Bristol-Myers Squibb Company
Term
5 years
9:00 AM ET 8-K
Other 8-K Filing Kustom Entertainment, Inc. KUST

Kustom Entertainment Other 8-K Filing

Kustom Entertainment, Inc. filed a Certificate of Amendment to its Articles of Incorporation to increase its total authorized capital stock from 11,333,334 shares to 1,200,000,000 shares. The new authorization includes 1,000,000,000 shares of common stock and 200,000,000 shares of preferred stock, following approval by stockholders at the 2026 annual meeting.

9:00 AM ET 8-K
Stock Buyback Sierra Bancorp BSRR

Sierra Bancorp Stock Buyback Update

Sierra Bancorp's Board of Directors authorized a new share repurchase program for up to 1,000,000 shares of common stock, effective from November 1, 2026, through October 31, 2027. Additionally, the company declared its 111th consecutive quarterly cash dividend of $0.27 per share, payable on November 9, 2026.

Term
through Oct 2027
8:55 AM ET 8-K
Investor Presentation Worthington Enterprises, Inc. WOR

Worthington Enterprises Investor Presentation

Worthington Enterprises announced that its CEO Joe Hayek and CFO Colin Souza will present at the Baird 2026 Global Industrial Conference on November 12, 2026. Additionally, the company will host an Investor and Analyst Day in New York City on November 10, 2026, to provide updates on its strategy, financial performance, and long-term growth opportunities.

8:52 AM ET 8-K
M&A Deal Crh Public Ltd Co CRH

Crh Public Ltd Signs $8.5B M&A Deal with Arcosa, Inc.

CRH completed its acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products, for an enterprise value of approximately $8.5 billion. The deal reinforces CRH's position as the top infrastructure player in North America and increases its exposure to major road, water, energy, and data projects.

Value
$8.5B
Counterparty
Arcosa, Inc.

“Arcosa is an excellent strategic fit for CRH and fully aligns with our growth ambitions. With high-quality aggregates assets and attractive positions in the growing U.S. energy transmission market, the acquisition strengthens our connected portfolio and reinforces our position as the #1 infrastructure player in North America. We look forward to welcoming our Arcosa colleagues into CRH and executing on the strong growth opportunities ahead.”

Jim Mintern, CRH CEO
8:49 AM ET 8-K
Financial Results Steele Bancorp Inc STLE

Steele Bancorp Financial Results

Steele Bancorp reported Q3 2026 net income of $5.46 million, a 60.1% decrease from the prior year period which was significantly impacted by one-time merger-related items. Net interest income grew 38.1% to $13.63 million, driven by loan and securities growth following the company's merger with Northumberland Bancorp.

Term
Q3 2026
8:44 AM ET 8-K
Business Update UWM Holdings Corp UWMC

UWM Holdings Business Update

UWM Holdings announced preliminary Q3 2026 results and updated its full-year 2026 outlook ahead of a $400 million rights offering. The company expects Q3 net income between $205M and $220M on loan origination volume of $33.4B, while lowering its full-year revenue guidance to $3.35B-$3.50B due to lower industry-wide origination volumes.

8:41 AM ET 8-K
Clinical Trial Data Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Clinical Trial Data

Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.

8:34 AM ET 8-K
Financial Results First National Corp FXNC

First National Financial Results

First National Corporation reported its financial results for the third quarter ended September 30, 2026. The filing includes a press release detailing the company's operations and financial condition for the period.

Term
Q3 2026
8:31 AM ET 8-K
M&A Deal Nordson Corp NDSN

Nordson Signs $168M M&A Deal with Contrinex Holding SA

Nordson Corporation, through its subsidiary Nordson London Limited, completed the acquisition of Switzerland-based Contrinex Holding SA for an enterprise value of approximately $168 million. Contrinex is a global leader in high-performance sensors for factory automation, generating approximately $50 million in annual revenue, and will be integrated into Nordson’s Advanced Technology Solutions segment.

Value
$168M
Counterparty
Contrinex Holding SA
8:31 AM ET 8-K
Business Update Microbot Medical Inc. MBOT

Microbot Medical Business Update

Microbot Medical announced its attendance at the SIR EDGE 2026 conference and the ACIR Annual Fall Conference to engage with interventional radiologists and hospital administrators. The company aims to leverage these events to generate sales leads and foster adoption of its FDA-cleared LIBERTY Endovascular Robotic System as it expands its U.S. commercial footprint.

8:30 AM ET 8-K
Dividend Lake Shore Bancorp, Inc. LSBK

Lake Shore Bancorp Dividend

Lake Shore Bancorp, Inc. declared a quarterly cash dividend of $0.09 per share on its outstanding common stock. The dividend is payable on November 11, 2026, to shareholders of record as of November 2, 2026.

8:27 AM ET 8-K
Leadership Change Great Elm Group, Inc. GEG

Great Elm Group Leadership Change

Eric Scheyer has notified the Board of Directors of Great Elm Group, Inc. of his decision not to stand for re-election at the company's 2026 Annual Meeting of Stockholders. He will continue to serve as a director until the date of the meeting, and his departure is not due to any disagreement with the company.

8:26 AM ET 8-K
Other 8-K Filing Winnebago Industries Inc WGO

Winnebago Industries Other 8-K Filing

Winnebago Industries entered into a cooperation agreement with activist investor Vision One, agreeing to nominate Jay L. Johnson to its Board of Directors at the 2026 Annual Meeting. The company also committed to proposing a phase-out of its classified board structure over three years and renaming its Audit Committee to the Audit and Finance Committee to enhance capital allocation oversight.

Counterparty
Vision One Fund, LP
8:15 AM ET 10-K
Financial Results Acuity Inc. (De) AYI

Acuity FY 2026 Results: Net Income $531M, Up 34.0% YoY

Acuity Inc. reported a 6.8% increase in net sales to $4.64 billion for fiscal 2026, driven by the acquisition of QSC and growth in Distech products. Net income rose 34% to $531.3 million, supported by higher operating profit and a $51.3 million tariff refund, despite higher selling and administrative expenses.

Key figure
Net income $531M · +34.0% YoY
8:09 AM ET 8-K
Leadership Change Fiserv Inc FISV

Fiserv Leadership Change

Fiserv appointed Raj Seshadri, a former Mastercard executive, to its board of directors effective November 30, 2026. Additionally, director Henrique De Castro informed the company he will not stand for re-election at the 2027 annual shareholder meeting, though he will serve out his current term.

8:07 AM ET 8-K
Financial Results LKQ Corp LKQ

LKQ Financial Results

LKQ Corporation reported preliminary Q3 2026 results showing a revenue decline to $3.32 billion and a net loss of $16M-$32M, primarily due to significant underperformance and operational disruptions in its European segment. In response, the company announced an immediate leadership overhaul, appointing Salvatore A. Abbate as the new CEO effective December 15, 2026, and withdrawing its full-year 2026 guidance.

“LKQ’s performance, particularly in Europe, has fallen significantly short of the Board’s expectations, and the Board is taking decisive action to address it.”

John Mendel, Chairman of the Board
8:06 AM ET 8-K
Financial Results Alpha Metallurgical Resources, Inc. AMR

Alpha Metallurgical Resources Financial Results

Alpha Metallurgical Resources announced preliminary financial results for the third quarter of 2026, reporting an expected net loss of $9.3 million. The results reflect stronger sales volumes of 3.9 million tons of coal but continued cost pressures and market volatility affecting realizations. The company plans to release its definitive third quarter results on November 6, 2026.

“As expected, our preliminary third quarter results reflect stronger volumes than in the first half but continued cost pressure. Our realizations for the quarter were influenced by the market volatility of the last few months. We look forward to providing more information about our results and outlook for 2027 when we announce our definitive third quarter financial results on November 6.”

Andy Eidson, Alpha’s chief executive officer
8:06 AM ET 8-K
Financial Results First Hawaiian, Inc. FHB

First Hawaiian Financial Results

First Hawaiian, Inc. reported Q3 2026 net income of $63.7 million, or $0.52 per diluted share, which included a $31.0 million tax benefit from a reorganization settlement. The company also declared a quarterly cash dividend of $0.26 per share and noted ongoing preparations for its acquisition of Tri Counties Bank.

Term
Q3 2026

“I’m pleased with the solid earnings we delivered this quarter and the continued trust our customers place in us. Our deposit growth in a competitive market reflects the strength of those relationships, and our balance sheet is well positioned to benefit from rising interest rates. As we prepare for the Tri Counties Bank acquisition, we’re focused on building on that foundation and the growth opportunities ahead.”

Bob Harrison, Chairman, President and Chief Executive Officer
8:03 AM ET 8-K
Capital Raise TPG Private Equity Opportunities, L.P.

TPG Private Equity Opportunities Capital Raise of $73.1M

TPG Private Equity Opportunities, L.P. raised $73.1 million in aggregate consideration through the sale of unregistered limited partnership units on October 1, 2026. The sale was part of the Fund's continuous private offering and included Class I, Class S, and Class F units. The broader T-POP Fund Complex issued interests totaling approximately $103.2 million during the same period.

Value
$73.1M
8:01 AM ET 8-K
Clinical Trial Data Oric Pharmaceuticals, Inc. ORIC

Oric Pharmaceuticals Clinical Trial Data

ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.